Cystic Fibrosis Foundation
Moderna’s updated COVID-19 mRNA vaccine approved by MHRA
The updated vaccine will be available to eligible groups as part of the 2026/27 NHS vaccination programme
MSD and Moderna announce potential new vaccine for melanoma
The mRNA-based therapy, used with Keytruda, is designed specifically for each patient
Moderna appoints Piyali Mukherjee as Head of Medical Affairs, Europe and Middle East
Mukherjee has previously held senior leadership roles at Moderna and GSK
Moderna and Merck announce data from melanoma combination therapy study
Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths
Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP
Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1
Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE
The rare inherited disease affects approximately 11,000 people in the UK
Vertex Pharmaceuticals’ cystic fibrosis therapy Alyftrek granted EC approval
The rare inherited disease affects more than 109,000 people worldwide
Moderna shares positive phase 3 results for mRNA flu vaccine candidate
More than 600,000 people in the US were hospitalised due to flu-related illness last year
Moderna’s RSV vaccine mRESVIA granted FDA approval to protect younger adults
The vaccine is already approved in the US for use in adults aged 60 years and older
Pfizer and Flagship Pioneering enter autoimmune disease partnership
More than 100 known types of autoimmune diseases affect over 50 million people in the US
Vertex’s triple combination cystic fibrosis therapy Alyftrek approved by MHRA
Over 11,000 people in the UK are affected by the rare genetic disease
Moderna’s RSV vaccine mRESVIA granted MHRA approval to protect older adults
RSV is responsible for 14,000 hospitalisations per year in UK adults aged 65 years and older